Discovery and characterization of QTX3544, a potent, selective, and orally bioavailable allosteric G12V preferring multi KRAS inhibitor

被引：0
|
作者：
Zhang, Yang W.
Vo, Elizabeth Donohue
Gan, Pei
Rominger, Dave
Silva, Jillian M.
Zhang, Yang J.
Pan, Christopher
Lee, Greg
Micozzi, John M.
Ben Reid
McDonough, Brooke
Sinha, Arghyotri
Hospital, Audrey
Krauth, Doug
Luengo, Juan I.
Kramer, Mike
Pitt, Cameron
Lin, Hong
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2024-LB163
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LB163
引用
下载
收藏
页数：2
相关论文
共 21 条
  • [1] Discovery and characterization of QTX3034, a potent, selective, and orally bioavailable allosteric KRAS inhibitor
    Zhang, Yang W.
    Rominger, Dave
    Vo, Elizabeth Donohue
    Silva, Jillian M.
    Zhang, Yang J.
    Lee, Greg
    Micozzi, John
    Reid, Ben
    McDonough, Brooke
    Hospital, Audrey
    Luengo, Juan I.
    Pitt, Cameron
    Lin, Hong
    CANCER RESEARCH, 2023, 83 (08)
  • [2] Discovery and characterization of QTX3046, a potent, selective, and orally bioavailable non-covalent KRASG12D inhibitor
    Vo, Elizabeth Donohue
    Zhang, Yang W.
    Rominger, Dave
    Silva, Jillian M.
    Zhang, Yang J.
    Lee, Greg
    Micozzi, John
    Reid, Ben
    McDonough, Brooke
    Hospital, Audrey
    Luengo, Juan I.
    Lin, Hong
    Pitt, Cameron
    CANCER RESEARCH, 2023, 83 (08)
  • [3] Discovery of SHR1127, an orally bioavailable, highly potent and selective KRAS G12D inhibitor
    Li, Xin
    Shen, Feng
    Zhang, Limin
    Wang, Wei
    Kong, Luyao
    Bao, Yong
    Mao, Yuchang
    Wang, Zaiyong
    Lin, Sophie
    Zhang, Zhe
    Feng, Jun
    Hu, Min
    He, Feng
    CANCER RESEARCH, 2024, 84 (06)
  • [4] Preclinical characterization of LY3962673, an orally bioavailable, highly potent, and selective KRAS G12D inhibitor
    Iyer, Chandrasekar
    Li, Binghui
    Stewart, Trent R.
    Wang, Tao
    Capen, Andrew
    Cavitt, Rachel
    Anderson, Bryan D.
    Bocchinfuso, Wayne
    Zhao, Gaiying
    Rodriguez, Michael J.
    Carballares, Santiago
    Cooke, Andrew
    Bondi, Robert
    Burns, Lee
    Kelamangalath, Lakshmi
    Wallace, Ross
    Kolakowski, Gabrielle
    Henry, James R.
    Si, Chong
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [5] Discovery and characterization of the potent, selective and orally bioavailable MMP inhibitor ABT-770
    Curtin, ML
    Florjancic, AS
    Heyman, HR
    Michaelides, MR
    Garland, RB
    Holms, JH
    Steinman, DH
    Dellaria, JF
    Gong, J
    Wada, CK
    Guo, Y
    Elmore, IB
    Tapang, P
    Albert, DH
    Magoc, TJ
    Marcotte, PA
    Bouska, JJ
    Goodfellow, CL
    Bauch, JL
    Marsch, KC
    Morgan, DW
    Davidsen, SK
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2001, 11 (12) : 1557 - 1560
  • [6] INCB161734: A novel, potent, and orally bioavailable KRAS G12D selective inhibitor demonstrates antitumor activity in KRAS G12D mutant tumors
    Farren, Matthew R.
    Roman, Valerie
    Gallion, Alexandra
    Allali-Hassani, Abdellah
    Sokolsky, Alexander
    Kong, Weixi
    Smith, Amanda
    Wang, Hui
    Correa, Gina
    Deller, Marc
    Epling, Leslie B.
    Procak, Jessica
    Zhang, Guofeng
    Pecko, Katherine
    Kennedy, Keith
    Boer, Jason
    Kurzeja-Lipinski, Kerri
    Covington, Maryanne
    Chen, Kwang-Jong
    Wallower, Renee
    Rocha, Jennifer
    Pan, Rina
    Perry, Anthony
    Yuska, Brad
    Wang, Xiaozhao
    Macarron, Ricardo
    Kim, Sunkyu
    CANCER RESEARCH, 2023, 84 (06)
  • [7] Discovery and Characterization of RGH-122, a Potent, Selective, and Orally Bioavailable V1a Receptor Antagonist
    Baska, Ferenc
    Bozo, Eva
    Szeleczky, Zsolt
    Szanto, Gabor
    Vukics, Krisztina
    Szakacs, Zoltan
    Domany-Kovacs, Katalin
    Kurko, Dalma
    Vass, Elemer
    Than, Marta
    Vastag, Monika
    Temesvari, Krisztina
    Levai, Sandor
    Halasz, Attila Sandor
    Kordas, Krisztina Szondine
    Roman, Viktor
    Greiner, Istvan
    Bata, Imre
    JOURNAL OF MEDICINAL CHEMISTRY, 2024, 67 (01) : 643 - 673
  • [8] Discovery of RGT-018: A potent, selective and orally bioavailable SOS1 inhibitor for mutant KRAS-driven cancers
    Xiao, Fei
    Wang, Kailiang
    Wang, Xinjuan
    Li, Huijuan
    Hu, Zhilong
    Huang, Wei
    Ren, Xiaoming
    Feng, Teng
    Yao, Lili
    Lin, Jing
    Li, Chunlai
    Mei, Liufeng
    Zhang, Zhuanzhuan
    Liu, Yangyang
    Chen, Xi
    Zhu, Xiaotian
    Zhong, Wenge
    Xie, Zhi
    CANCER RESEARCH, 2023, 83 (07)
  • [9] Discovery of TK-642 as a highly potent, selective, orally bioavailable pyrazolopyrazine-based allosteric SHP2 inhibitor
    Tang, Kai
    Wang, Shu
    Feng, Siqi
    Yang, Xinyu
    Guo, Yueyang
    Ren, Xiangli
    Bai, Linyue
    Yu, Bin
    Liu, Hong-Min
    Song, Yihui
    ACTA PHARMACEUTICA SINICA B, 2024, 14 (08) : 3624 - 3642
  • [10] Discovery and Characterization of ZL-2201, a Potent, Highly Selective, and Orally Bioavailable Small-molecule DNA-PK Inhibitor
    Lal, Shruti
    Bhola, Neil E.
    Sun, Bee-Chun
    Chen, Yuping
    Huang, Tom
    Morton, Vivian
    Chen, Kevin X.
    Xia, Shanghua
    Zhang, Haoyu
    Parikh, Nehal S.
    Ye, Qiuping
    Veiby, O. Petter
    Bellovin, David I.
    Ji, Yuhua
    CANCER RESEARCH COMMUNICATIONS, 2023, 3 (09): : 1731 - 1742
123